Back to results
US 2010/0144706 A1Published application
Compounds
AssigneeBoehringer Ingelheim International GmbH
InventorsStephan Karl Zahn, Guido Boehmelt, Ulrich Guertler, Andreas Mantoulidis, Andreas Schoop, Flavio Solca, Ulrike Tontsch-Grunt, Matthias Treu
Life of this patent
Estimating the term…
Abstract
The present invention encompasses compounds of general formula (1) wherein R1 to R4, X and n are defined as in claim 1, which are suitable for the treatment of ailments characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
Claims8
A compound of the formula (1),
- wherein
- X denotes N or CH, and
- R1 denotes a group selected from among halogen and C1-4-haloalkyl, and
- R2 denotes a group selected from among hydrogen and C1-6-alkyl, and
- R3 denotes a group selected from among Ra, —NHRc, and —ORc when X is CH, and
- R3 denotes a group selected from among Ra, —NHRc, —ORc and —C(O)NRcRc when X is N, and
- R4 denotes a group selected from among halogen, C1-4-alkyl, C1-3-haloalkyloxy and —ORf, and
- Ra denotes a group, optionally substituted by one or more identical or different Rc and/or Rb, which is selected from among C1-6-alkyl, C3-10-cycloalkyl, C4-16-cycloalkylalkyl, C6-10-aryl, C7-16-arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl and 6-18 membered heteroarylalkyl, and
- each Rb denotes a suitable group and each is independently selected from among ═O, —ORc, C1-3-haloalkyloxy, —OCF3, ═S, ═NRc, ═NORc, —NRcRc, halogen, —CF3, —CN, —NC, —OCN, —SCN, —NO2, —S(O)Rc, —S(O)2Rc, —S(O)2ORc, —S(O)NRcRc, —S(O)2NRcRc, —OS(O)Rc, —OS(O)2Rc, —OS(O)2ORc, —OS(O)2NRcRc, —C(O)Rc, —C(O)ORc, —C(O)NRcRc, —CN(Rf)NRcRc, —CN(OH)Rc, —CN(OH)NRcRc, —OC(O)Rc, —OC(O)ORc, —OC(O)NRcRc, —OCN(Rf)NRcRc, —N(Rf)C(O)Rc, —N(Rf)C(S)Rc, —N(Rf)S(O)2Rc, —N(Rf)C(O)ORc, —N(Rf)C(O)NRcRc, —[N(Rf)C(O)]2Rc, —N[C(O)]2Rc, —N[C(O)]2ORc, —[N(Rf)C(O)]2ORc and —N(Rf)CN(Rf)NRcRc, and
- each Rc independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different Rd and/or Re selected from among C1-6-alkyl, C3-10-cycloalkyl, C4-11-cycloalkylalkyl, C6-10-aryl, C7-16-arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl and 6-18 membered heteroarylalkyl, and
- each Rd independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different Re and/or Rf selected from among C1-6-alkyl, C3-8-cycloalkyl, C4-11-cycloalkylalkyl, C6-10-aryl, C7-16-arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl and 6-18 membered heteroarylalkyl, and
- each Re is a suitable group and each is independently selected from among ═O, —ORf, C1-3-haloalkyloxy, —OCF3, ═S, —SRf, ═NRf, ═NORf, —NRfRf, halogen, —CF3, —CN, —NC, —OCN, —SCN, —NO2, —S(O)Rf, —S(O)2Rf, —S(O)2ORf, —S(O)NRfRf, —S(O)2NRfRf, —OS(O)Rf, —OS(O)2Rf, —OS(O)2ORf, —OS(O)2NRfRf, —C(O)Rf, —C(O)ORf, —C(O)NRfRf, —CN(Rg)NRfRf, —CN(OH)Rf, —C(NOH)NRfRf, —OC(O)Rf, —OC(O)ORf, —OC(O)NRfRf, —OCN(Rg)NRfRf, —N(Rg)C(O)Rf, —N(Rg)C(S)Rf, —N(Rg)S(O)2Rf, —N(Rd)C(O)ORf, —N(Rg)C(O)NRfRf, and —N(Rg)CN(Rf)NRfRf, and
- each Rf independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different Rg selected from among C1-6-alkyl, C3-8-cycloalkyl, C4-11-cycloalkylalkyl, C6-10-aryl, C7-16-arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl and 6-18 membered heteroarylalkyl, and
- each Rg independently of one another denotes hydrogen, C1-6-alkyl, C3-8-cycloalkyl, C4-11-cycloalkylalkyl, C6-10-aryl, C7-16-arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkyl, 5-12 membered heteroaryl and 6-18 membered heteroarylalkyl
- n denotes 0, 1 or 2,
- optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts thereof, with the proviso that the following compounds
- 2-[2-(4-[1,4]diazepan-1-yl-3-fluorophenylamino)-5-trifluoromethylpyrimidin-4-ylamino]-cyclopentanecarboxylic acid-isopropylamide,
- 2-{2-[3-fluoro-4-(4-methyl-[1,4]diazepan-1-yl)-phenylamino]-5-trifluoromethyl-pyrimidin-4-ylamino}-cyclopentanecarboxylic acid-isopropylamide and
- 2-{2-[4-(3-dimethylamino-2,2-dimethyl-propylamino)-3-fluoro-phenylamino]-5-trifluoromethyl-pyrimidin-4-ylamino}-cyclopentanecarboxylic acid-isopropylamide, are not included.
16 more elements
5-9. (canceled)
Dependencies are inferred from the claim text.